TIME
THE CONTINUING RAVAGES OF AIDS HAVE FORCED the U.S. Food and Drug Administration to further streamline drug-approval procedures. Last week a panel of experts recommended that the government agency give its conditional blessing to dideoxycytidine, or DDC. Although preliminary studies indicate that this antiviral medication may not work as well as AZT which still ranks as the premier AIDS treatment, the combination of drugs seems to rejuvenate some of the immune cells that are normally destroyed during the course of the disease.
If the FDA approves DDC the manufacturer, Hoffmann-La Roche, will be required to submit further studies on the drug’s safety and efficacy.
More Must-Reads from TIME
- Cybersecurity Experts Are Sounding the Alarm on DOGE
- Meet the 2025 Women of the Year
- The Harsh Truth About Disability Inclusion
- Why Do More Young Adults Have Cancer?
- Colman Domingo Leads With Radical Love
- How to Get Better at Doing Things Alone
- Michelle Zauner Stares Down the Darkness
Contact us at letters@time.com